Figures & data
Note: Women receiving 91-day extended-regimen COC with 30 µg EE/150 µg LNG for 84 days and EE 10 µg for 7 days showed a 10% increase in the likelihood of reporting no scheduled bleeding (OR =1.102 [95% CI: 1.006–1.206]) and a 9% increase in the likelihood of reporting no scheduled spotting (OR =1.085 [95% CI: 1.005–1.170]) for each additional 91-day cycle completed.
Abbreviations: COC, combined oral contraception; EE, ethinyl estradiol; LNG, levonorgestrel.
Abbreviations: COC, combined oral contraception; EE, ethinyl estradiol; LNG, levonorgestrel.
Note: Women receiving 91-day extended-regimen COC with 30 µg EE/150 µg LNG for 84 days and EE 10 µg for 7 days showed a 53% increase in the likelihood of reporting 0 to ≤6 days of unscheduled bleeding per 91-day cycle (OR =1.531 [95% CI: 1.393–1.683]).
Abbreviations: COC, combined oral contraception; EE, ethinyl estradiol; LNG, levonorgestrel.
Abbreviations: COC, combined oral contraception; EE, ethinyl estradiol; LNG, levonorgestrel.
Note: Women receiving 91-day extended-regimen COC with 30 µg EE/150 µg LNG for 84 days and EE 10 µg for 7 days showed a 31% increase in the odds of reporting 0 to ≤6 days of unscheduled spotting per 91-day cycle (OR =1.307 [95% CI: 1.205–1.418]).
Abbreviations: COC, combined oral contraception; EE, ethinyl estradiol; LNG, levonorgestrel.
Abbreviations: COC, combined oral contraception; EE, ethinyl estradiol; LNG, levonorgestrel.